DEBORAH GADDIS: Open Payments
NPI 1619246873 · KIMBALL, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$619 in 31 payments from 11 companies in 2025. Trend: 2023 $873 · 2024 $628 · 2025 $619
Food & beverage: $619
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 9 | $181 |
| PFIZER INC. | 4 | $82 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $76 |
| Lilly USA, LLC | 3 | $56 |
| Sumitomo Pharma America, Inc. | 2 | $44 |
| Xeris Pharmaceuticals, Inc. | 2 | $43 |
| AstraZeneca Pharmaceuticals LP | 2 | $41 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $41 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
Products named: Rybelsus, Kerendia, Ozempic, MOUNJARO, ELIQUIS, GEMTESA, GVOKE HYPOPEN, XIFAXAN.
Industry payments across TN — which companies pay providers there.
